Department of Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Ave., Boston, MA, 02215, USA.
Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, 330 Brookline Ave., Dana 603, Boston, MA, 02215, USA.
Dig Dis Sci. 2019 Aug;64(8):2338-2350. doi: 10.1007/s10620-019-5457-5. Epub 2019 Jan 10.
Fatigue is the most common complication of primary biliary cholangitis (PBC) and can be debilitating. Numerous interventions have been trialed targeting several proposed mechanisms of PBC-associated fatigue. We sought to summarize and perform a meta-analysis to determine the efficacy of these interventions.
A comprehensive database search was conducted from inception through March 27, 2018. The primary outcome was proportion of fatigued patients or reduction in degree of fatigue. Adverse events were a secondary outcome. We assessed studies for risk of bias, graded quality of evidence, and used meta-analysis to obtain overall effect by pooling studies of the same class.
We identified 16 studies evaluating ursodeoxycholic acid (UDCA) (7), liver transplantation (2), serotonin reuptake inhibitors (2), colchicine (1), methotrexate (1), cyclosporine (1), modafinil (1), and obeticholic acid (1). On meta-analysis, UDCA was not associated with a reduction in risk of fatigue (RR = 0.86, 95% CI 0.69-1.08, p = 0.19, I = 56.2%). While liver transplantation did reduce degree of fatigue (SMD - 0.57, 95% CI - 0.89 to - 0.24, p = 0.001, I = 67.3%), fatigue did not return to baseline indicating the underlying cause may not be addressed.
While there is some improvement in fatigue with liver transplantation, there is a lack of high-quality evidence supporting the efficacy of any other intervention in the treatment of PBC-related fatigue. Further research into the underlying pathophysiology may help guide future trials.
疲劳是原发性胆汁性胆管炎(PBC)最常见的并发症,可能使人虚弱。已经尝试了许多干预措施,针对 PBC 相关疲劳的几个提出的机制。我们旨在总结并进行荟萃分析,以确定这些干预措施的疗效。
从成立到 2018 年 3 月 27 日进行了全面的数据库搜索。主要结果是疲劳患者的比例或疲劳程度的降低。不良事件是次要结果。我们评估了研究的偏倚风险,分级证据质量,并使用荟萃分析通过汇总同一类别的研究来获得总体效果。
我们确定了 16 项评估熊去氧胆酸(UDCA)(7)、肝移植(2)、5-羟色胺再摄取抑制剂(2)、秋水仙碱(1)、甲氨蝶呤(1)、环孢素(1)、莫达非尼(1)和奥贝胆酸(1)的研究。荟萃分析显示,UDCA 与降低疲劳风险无关(RR=0.86,95%CI 0.69-1.08,p=0.19,I=56.2%)。虽然肝移植确实降低了疲劳程度(SMD-0.57,95%CI-0.89 至-0.24,p=0.001,I=67.3%),但疲劳并未恢复到基线,表明潜在原因可能未得到解决。
虽然肝移植后疲劳有所改善,但缺乏支持任何其他干预措施治疗 PBC 相关疲劳疗效的高质量证据。进一步研究潜在的病理生理学可能有助于指导未来的试验。